Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Shixia Wang

Yanhui Li

Chunlei Li

Yajuan Wang

Caixia Wang

Min Liang

Yongfeng Li

Jing Yuan

Xuekun Yao

Hongmei Luo

Jianfei Xue

Zhibin Meng

Shan Chen

Yumei Wang

Kun Lou

Yueying Peng

Dongjian Chen

Hongmei Lin

Shasha Yang

Shujie Yan

Xuefang Xia

Meng Zhou

Xiaoli Wang

Yanling Du

Qiushuang Jin

Lingling Wang

Xiugao Yang

Disclosed is a use of a liposomal pharmaceutical preparation of mitoxantrone in the preparation of a medicament for treating lymphoma, wherein the lymphoma is preferably non-Hodgkin's lymphoma, further preferably aggressive non-Hodgkin's lymphoma, more preferably diffuse large B-cell lymphoma or peripheral T-cell lymphoma, and more further preferably relapsed or refractory diffuse large B-cell lymphoma or peripheral T-cell lymphoma. The mitoxantrone liposomes are used as single anti-tumor therapeutic agent without being combined with other anti-tumor agents.

Use of mitoxantrone liposome for treating non-Hodgkin's lymphoma

Purified therapeutic nanoparticles are provided herein. Such nanoparticles comprise an active pharmaceutical ingredient and human serum albumin, wherein the weight ratio of human serum albumin to the active ingredient in the therapeutic nanoparticles is from 0.01:1 to 1:1, and wherein the nanoparticles are substantially free of free human serum albumin that is not incorporated in the nanoparticles. The present disclosure also provides pharmaceutical compositions that comprise the purified therapeutic nanoparticles and are also substantially free of free human serum albumin. Methods for preparing and using the purified therapeutic nanoparticles and compositions thereof are also provided.

Purified therapeutic nanoparticles and preparation methods thereof

Growing community of inventors

Shijiazhuang, China

Shixia Wang